Recently a consolidation motion was filed for all federal Androgel lawsuits to become part of an MDL, or multidistrict litigation.

Hot on the heels of that motion, a second motion has been filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) requesting that all testostereone therapy lawsuits be centralized before one judge as a single coordinated proceeding.

If granted, this MDL would be similar to the Byetta, Victoza, Januvia MDL, where the type 2 diabetic drugs have been alleged to have caused pancreatic cancer. The Incretin Mimetic MDL is consolidated in Southern District of Californian, in San Diego.

Benefits of MDL Consolidation

Centralizing the cases reduces the duplicative discovery and avoids conflicting rulings from different judges. Following pretrial proceedings and a series of test trials, known as bellwether trials, if the parties fail to reach testosterone settlement, the individual claims may be remanded back to the U.S. District Courts for separate trials.

Testosterone Therapy Litigation

There are more than 50 Testosterone Therapy product liability lawsuits filed in U.S. District Courts. Injured men have alleged that they suffered a heart attack, stroke, and blood clots such as deep vein thrombosis and pulmonary embolism, caused by side effects of testosterone replacement therapy (TRT).

The majority of the lawsuits involve injury from the use of Androgel. The remainder have been filed by users of different testosterone gels, creams and patches, including Testim, Axiron, and Androderm.

Rafael Barrios requested that one centralized proceeding be established for claims involving all different manufacturers of testosterone replacement therapy (TRT). Barrios claims that his injury occurred following use of both Androgel and Testim, which are two different products made by different drug makers.

JPML Androgel Hearing

See original here:

Androgel Testosterone Injury Federal Consolidation